Nautilus Biotechnology (NAUT) Common Equity (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Common Equity of $131.1 million for Q2 2026, down 9.21% sequentially from $144.4 million in Q1 2026, and down 27.6% YoY from $181.1 million in Q2 2025.
Nautilus Biotechnology (NAUT) Common Equity (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Common Equity for 7 years, with the latest figure at $131.1 million in Q2 2026.
- Quarterly Common Equity fell 27.6% year-over-year to $131.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $131.1 million (down 27.6% YoY) and the FY2025 annual result came in at $157.0 million, down 24.8% from the prior year.
- Common Equity declined to $131.1 million in Q2 2026 per NAUT's latest filing, from $144.4 million in the prior quarter.
- Over five years, Common Equity peaked at $349.7 million in Q1 2022 and troughed at $131.1 million in Q2 2026.
- A 5-year average of $242.1 million and a median of $242.4 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2026: Common Equity jumped 1050.43% in 2022, then slipped 27.6% in 2026.
- Over 5 years, Common Equity stood at $314.9 million in 2022, then dropped by 15.74% to $265.4 million in 2023, then decreased by 21.34% to $208.7 million in 2024, then decreased by 24.8% to $157.0 million in 2025, then decreased by 16.47% to $131.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $131.1 million, $144.4 million, and $157.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Nautilus Biotechnology | 114.43 Mn | 114.43 Mn | 175,000.00 | 131.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 131.11 Mn |
| Mar 31, 2026 | 144.42 Mn |
| Dec 31, 2025 | 156.97 Mn |
| Sep 30, 2025 | 169.14 Mn |
| Jun 30, 2025 | 181.09 Mn |
| Mar 31, 2025 | 194.44 Mn |
| Dec 31, 2024 | 208.73 Mn |
| Sep 30, 2024 | 223.43 Mn |
| Jun 30, 2024 | 235.28 Mn |
| Mar 31, 2024 | 249.49 Mn |
| Dec 31, 2023 | 265.35 Mn |
| Sep 30, 2023 | 277.27 Mn |
| Jun 30, 2023 | 289.67 Mn |
| Mar 31, 2023 | 303.72 Mn |
| Dec 31, 2022 | 314.92 Mn |
| Sep 30, 2022 | 325.34 Mn |
| Jun 30, 2022 | 337.56 Mn |
| Mar 31, 2022 | 349.71 Mn |
| Dec 31, 2021 | 363.58 Mn |
| Sep 30, 2021 | 377.85 Mn |